|
Session Title |
Talk Title |
View |
Curriculum Ref |
3487 |
Paul Wood Keynote Lecture |
Mechanisms of atrial arrhythmias: from the simple to the complex. Implications for treatment and prevention |
|
|
3176 |
Opening Ceremony |
Welcome to the BCS Annual Conference 2015 |
|
|
3178 |
Opening Ceremony |
Where are we going with molecular medicine? |
|
|
3220 |
Innovations in Cardio-Oncology |
Surveillance with cardiac biomarkers to predict cardiotoxicity |
|
|
3233 |
Innovations in Cardio-Oncology |
Translational insights into anthracycline cardiotoxicity |
|
|
3234 |
Innovations in Cardio-Oncology |
New therapeutic strategies to protect the heart from cancer drugs |
|
|
3222 |
Innovations in treating acute coronary syndromes |
Anti-thrombotic therapy for ACS |
|
|
3223 |
Innovations in treating acute coronary syndromes |
Coronary Physiology Guiding Management in ACS |
|
|
3225 |
Innovations in interventional cardiology |
Novel intracoronary imaging |
|
|
3236 |
Innovations in interventional cardiology |
Bioresorbable stent technology |
|
|
3933 |
Innovations in interventional cardiology |
Percutaneous mechanical support in Cardiogenic shock and high risk PCI |
|
|
3238 |
Genetic susceptibility to cardiac arrhythmias |
Early repolarisation abnormalities in risk stratification of SCD |
|
|
3239 |
Genetic susceptibility to cardiac arrhythmias |
Genetic determinants of atrial fibrillation |
|
|
3229 |
Genetic susceptibility to cardiac arrhythmias |
New insights into the Brugada syndrome |
|
|
3230 |
Innovations in heart failure therapy |
Telemonitoring for heart failure |
|
|
3240 |
Innovations in heart failure therapy |
Vagal stimulation: nectar for heart failure? |
|
|
3241 |
Innovations in heart failure therapy |
Stem cell therapy for heart failure |
|
|
3242 |
Innovations in the diagnosis and treatment of cardiomyopathies |
New insights into pathogenesis and risk stratification in dilated cardiomyopathy |
|
|
3245 |
Innovations in the diagnosis and treatment of cardiomyopathies |
Pathogenesis of familial restrictive cardiomyopathy |
|
|
5068 |
Innovations in the diagnosis and treatment of cardiomyopathies |
Gene therapy for hypertrophic cardiomyopathy: targeting the cause |
|
|
3474 |
Innovations in the diagnosis and treatment of cardiomyopathies |
|
|
|
3246 |
Innovations in cardiovascular risk prevention |
Novel therapeutic targets for hypertension |
|
|
3247 |
Innovations in cardiovascular risk prevention |
PCSK9 inhibition for hyperlipidaemia |
|
|
3249 |
Innovations in cardiovascular risk prevention |
Lipoprotein a: a novel therapeutic target |
|
|
3268 |
Read with the Experts - multi-modality imaging - Session 1 |
Case 5: |
|
|
3286 |
Call the Cardiology Registrar |
Chest pain in pregnancy |
|
|
3287 |
Call the Cardiology Registrar |
PAF in a non-compliant patient |
|
|
3289 |
Call the Cardiology Registrar |
Palpitations in a patient with congenital heart disease |
|
|
5136 |
SAC session |
BJCA Survey |
|
|
5140 |
SAC session |
|
|
|
3294 |
The heart in systemic disease |
Amyloid and the heart |
|
|
3295 |
The heart in systemic disease |
Malignancy and the heart |
|
|
3322 |
Managing NSTEMI in 2015 |
Making a diagnosis |
|
|
3324 |
Managing NSTEMI in 2015 |
Should risk stratification influence therapy? |
|
|
3326 |
Managing NSTEMI in 2015 |
What is optimal therapy? |
|
|
3342 |
Shared care in ACHD |
Specialist input: what and to whom to refer |
|
|
3344 |
Shared care in ACHD |
Recognising signs of impending doom |
|
|
3346 |
Shared care in ACHD |
Palliation and end of life care |
|
|
3352 |
Challenges in the management of valve disease |
Aortic stenosis - low flow, low gradient |
|
|
3354 |
Challenges in the management of valve disease |
Mitral regurgitation - in ischaemic heart disease |
|
|
3356 |
Challenges in the management of valve disease |
Mechanical heart valves - anticoagulation for PCI and peri-operative care |
|
|
3362 |
New technology in clinical practice: now you see it, now you don’t |
Renal Denervation Therapy |
|
|
3364 |
New technology in clinical practice: now you see it, now you don’t |
The leadless pacemaker |
|
|
3365 |
New technology in clinical practice: now you see it, now you don’t |
The bioresorbable stent |
|
|
3367 |
New technology in clinical practice: now you see it, now you don’t |
Circulatory Support Devices |
|
|
3373 |
Reducing the burden of atrial fibrillation |
Treating the patient to reduce progression |
|
|
3374 |
Reducing the burden of atrial fibrillation |
Avoiding thrombo-embolic complications |
|
|
3381 |
The Transplant Cycle |
From Bed to Bike |
|
|
5153 |
The Transplant Cycle |
|
|
|
3925 |
The Transplant Cycle |
From Newcastle to Bristol and Back |
|
|
3926 |
The Transplant Cycle |
The Heart Transplant Patient & the Cardiologist |
|
|
3409 |
Hypertension update for cardiologists 2015 |
Why should cardiologists be interested in hypertension? |
|
|
3411 |
Hypertension update for cardiologists 2015 |
Diagnosing hypertension |
|
|
3413 |
Hypertension update for cardiologists 2015 |
Treating Hypertension |
|
|
3434 |
Valve disease intervention |
Who should you refer directly for TAVI in 2015? |
|
|
3435 |
Valve disease intervention |
Do we really need GA & surgical cover for TAVI any longer in 2015? |
|
|
3436 |
Valve disease intervention |
Where have we to go with percutaneous treatment of mitral regurgitation? |
|
|
3509 |
Hypertrophic cardiomyopathy: Gene to Bedside |
Clinical application of genetic testing in HCM |
|
|
3511 |
Hypertrophic cardiomyopathy: Gene to Bedside |
Abnormalities in Ca2+ handling and potential for novel therapies |
|
|
3513 |
Hypertrophic cardiomyopathy: Gene to Bedside |
The role of metabolism in HCM |
|
|
3514 |
Hypertrophic cardiomyopathy: Gene to Bedside |
Mechanistic and prognostic potential of CMR in hypertrophic cardiomyopathy |
|
|
3515 |
Hypertrophic cardiomyopathy: Gene to Bedside |
25 years of research into Hypertrophic Cardiomyopathy |
|
|
3528 |
ESC Guidelines on hypertrophic cardiomyopathy and aortic diseases |
Hypertrophic cardiomyopathy: the guidelines |
|
|
3539 |
ESC Guidelines on hypertrophic cardiomyopathy and aortic diseases |
Aortic Diseases: the guidelines |
|
|
3691 |
ESC Guidelines on hypertrophic cardiomyopathy and aortic diseases |
ESC guidelines on HCM: implications for UK practice |
|
|
3692 |
ESC Guidelines on hypertrophic cardiomyopathy and aortic diseases |
ESC guidelines on aortic disease: implications for UK practice |
|
|
3791 |
MDT Live 1. Intervention |
Moderator |
|
|
5164 |
Top 10 Trials |
Artwork: SCOT-HEART |
|
|
5178 |
Top 10 Trials |
Electrics: Discussant |
|
|
5181 |
Top 10 Trials |
Pump: Discussant |
|
|
5186 |
Top 10 Trials |
Electrics: CRYSTAL-AF |
|
|
5187 |
Top 10 Trials |
Electrics: AATAC-AF |
|
|
5188 |
Top 10 Trials |
Drugs: PEGASUS TIMI-54 |
|
|
5189 |
Top 10 Trials |
Drugs: OSLER |
|
|
5190 |
Top 10 Trials |
Plumbing: DAPT |
|
|
5192 |
Top 10 Trials |
Pump: PARADIGM |
|
|
5193 |
Top 10 Trials |
Pump: CONFIRM HF |
|
|
5241 |
Top 10 Trials |
Artwork:PROMISE |
|
|
5242 |
Top 10 Trials |
Drugs: Discussant |
|
|
3822 |
MDT Live 2. Arrhythmias |
Case presentation |
|
|
3722 |
A survival guide to the medicolegal minefield: courtroom scenarios |
The mysteries explained |
|
|
3757 |
MDT Live 3. Heart Failure |
|
|
|
3818 |
MDT Live 3. Heart Failure |
Moderator |
|
|
3893 |
MDT Live 3. Heart Failure |
|
|
|
3845 |
The BCS Quiz |
Quizmaster |
|
|